AGP Picks
View all

HYTN Innovations Inc. and Peptide Development Labs Inc. Announce Closing of the Arrangement and Concurrent Financing

News originally published by

GlobeNewswire

VANCOUVER, British Columbia, Nov. 19, 2026 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN) (OTC Pink: HYTNF) (FSE: 85W0) (“HYTN”) and Peptide Development Labs Inc. (CSE: PEPT) (“PDL”) are pleased to announce that they have closed their previously announced arrangement effective at 12:01 a.m. on November 17, 2026 (the “Effective Time”).

Arrangement

Under the statutory plan of arrangement involving HYTN and PDL (the “Arrangement”), the shareholders of HYTN received common shares of PDL (“PDL Common Shares”) by way of a share exchange, pursuant to which each existing share of HYTN held at the Effective Time (a “HYTN Common Share”) was exchanged for one “new” share of HYTN (“New HYTN Common Share”) and 0.0555555555555556 of a PDL Common Share.

The Canadian Securities Exchange (the “CSE”) granted conditional acceptance of the Arrangement on November 11, 2026. The listing of the PDL Common Shares on the CSE under the symbol “PEPT” is subject to PDL meeting the listing requirements of the CSE, and PDL anticipates being listed on November 20, 2026.

Concurrent Financing

Concurrent with closing of the Arrangement, PDL completed a non-brokered private placement (the “Concurrent Financing”) for gross proceeds of approximately $3,000,000 through the issuance of 6,000,000 units of PDL (“PDL Units”) at an issue price of $0.50 per PDL Unit. Each PDL Unit shall entitle the holder thereof to one PDL Common Share and one-half of one PDL Common Share purchase warrant (each whole purchase warrant, a “PDL Warrant”). Each whole PDL Warrant shall be exercisable for a period of 24 months for one PDL Common Share at an exercise price of $0.75.

The net proceeds from the Concurrent Financing will be used to pursue the development milestones set out in HYTN’s management information circular dated October 16, 2026 (the “Circular”), including qualification and product setup, engineer and validation, regulatory and clinical readiness, and formal clinical development.

All securities issued under the Concurrent Financing are subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities laws.

Stock Symbols

New HYTN Common Shares will trade on the CSE under HYTN’s current ticker symbol of “HYTN”. The CUSIP number assigned to the New HYTN Common Shares is 40443L203 (ISIN: CA40443L203).

Once listed, the PDL Common Shares will trade on the CSE under the ticker symbol “PEPT”. The CUSIP number assigned to the PDL Common Shares is 713467108 (ISIN: CA713467108).

Trading Information

It is expected that the PDL Common Shares will begin trading on the CSE on November 20, 2026.

Where existing HYTN Common Shares (CUSIP 40443L) are held through a broker, such broker, or the depositary with which the broker holds such HYTN Common Shares, will be responsible for dealing with the exchange of these HYTN Common Shares for New HYTN Common Shares and the distribution of PDL Common Shares on the HYTN Shareholder’s behalf.

HYTN has mailed letters of transmittal to all eligible registered shareholders. To receive Direct Registration System (“DRS”) statements representing New HYTN Common Shares and PDL Common Shares, registered shareholders must duly complete the letter of transmittal and either provide their DRS account number or surrender their existing certificates for HYTN Common Shares, as applicable, and deliver them to Odyssey Trust Company (“Depositary”) at the address shown on the letter of transmittal. Upon surrender to the Depositary for cancellation of a certificate representing HYTN Common Shares (if any), together with a properly executed letter of transmittal, the registered shareholder will be entitled to receive, and the Depositary will deliver to such holder, a statement representing the number of New HYTN Common Shares and the number (rounded down to the next lesser whole number, subject to the treatment of fractional PDL Common Shares under the terms of the plan of arrangement, attached as Schedule B to the Circular) of New HYTN Common Shares and PDL Common Shares that such holder has the right to receive pursuant to the plan of arrangement and the surrendered certificate (if any) will be cancelled. The letter of transmittal was filed on HYTN’s SEDAR+ profile on October 22, 2026 and is available at www.sedarplus.ca.

About HYTN Innovations Inc.

HYTN formulates, manufactures, markets, and sells premium products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids. HYTN’s mission is to become the top provider of these products in all federally regulated markets. To achieve this, HYTN focuses on identifying market opportunities and quickly bringing its innovative products to market through its elevated development platform.

About Peptide Development Labs Inc.

PDL is a Canadian pharmaceutical development company focused on advancing investigational peptide-based drug candidates through established regulatory pathways. PDL’s mission is to develop peptide candidates that may address defined areas of unmet clinical need within a conventional pharmaceutical framework. To achieve this, PDL focuses on advancing its investigational subcutaneous BPC-157 drug candidate for refractory ligament disorders through GMP-controlled supply, pharmaceutical quality systems, physician-led access, structured data generation and formal clinical development.

For more information contact:
Elliot McKerr
Chief Executive Officer
HYTN Innovations Inc.

or

Fabian Monaco
Chief Executive Officer
Peptide Development Labs Inc.

HYTN Investor Relations:
1.866.590.9289
investments@hytn.life

The CSE has not reviewed, approved, or disapproved the contents of this press release.

Forward-Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking information”). Forward-looking information in this press release includes, but is not limited to, statements regarding the final acceptance of the Arrangement by the Canadian Securities Exchange (the “CSE”); the listing of the PDL Common Shares on the CSE and PDL’s satisfaction of the applicable listing requirements of the CSE; the anticipated commencement of trading of the New HYTN Common Shares and PDL Common Shares on the CSE; the anticipated use of the net proceeds from the Concurrent Financing; and PDL’s plans to pursue its development milestones, including qualification and product setup, engineering and validation, regulatory and clinical readiness and formal clinical development.

Forward-looking information is typically identified by the use of words such as “expects”, “intends”, “plans”, “anticipates”, “believes”, “proposes”, “estimates”, “may”, “will”, “should”, “could” or similar expressions, including negative variations thereof, or statements that certain actions, events or results “will”, “may”, “would” or “should” occur or be achieved.

Forward-looking information is based on a number of material factors and assumptions, including, without limitation, that the CSE will provide final acceptance of the Arrangement; that PDL will satisfy the applicable listing requirements of the CSE; that the New HYTN Common Shares and PDL Common Shares will commence trading on the CSE within the timeframe currently anticipated; that the net proceeds of the Concurrent Financing will be available and used as currently anticipated; and that PDL will be able to pursue its development milestones as currently contemplated.

Although HYTN and PDL believe that the expectations and assumptions underlying such forward-looking information are reasonable as of the date hereof, such expectations and assumptions may prove to be incorrect, and no assurance can be given that the events anticipated by such forward-looking information will transpire or occur within the timeframes anticipated.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or events to differ materially from those anticipated in such forward-looking information. Such risks and uncertainties include, without limitation: the risk that final acceptance of the Arrangement by the CSE is not obtained on a timely basis or at all; the risk that PDL does not satisfy the applicable listing requirements of the CSE; the risk that the New HYTN Common Shares or PDL Common Shares do not commence trading on the CSE when anticipated; the risk that the net proceeds of the Concurrent Financing are not sufficient to pursue PDL’s development milestones as currently contemplated; risks associated with early-stage drug development; regulatory risks, including those relating to clinical development pathways, approvals and compliance requirements; risks relating to reliance on third-party manufacturers, service providers and supply chains; operational and execution risks; intellectual property risks; and general economic, market and financing conditions.

Readers are cautioned that the foregoing list of factors, assumptions and risks is not exhaustive. Additional information regarding the risks and uncertainties applicable to HYTN and PDL is contained in the Circular and other public disclosure documents available under HYTN’s issuer profile on SEDAR+.

The forward-looking information contained in this press release is made as of the date hereof, and HYTN and PDL undertake no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Readers are cautioned not to place undue reliance on forward-looking information.


Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health Digest Cook Islands

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.